Light AI Announces C$5,000,000 Secured Convertible Debenture Unit Financing
Light AI’s C$5 Million Lifeline Comes With Dilutive Terms and Board Strings as Cash Burn Intensifies
Light AI Inc. announced a C$5,000,000 secured convertible debenture unit financing with MV Capital LP on May 21, 2026. The offering comprises 5,000 units at $1,000 each. Each unit includes a 12% secured convertible debenture (24‑month maturity, interest compounded quarterly) and 8,000 warrants with a $0.25 exercise price (36‑month term). The debenture converts at $0.125 per share, and the company can force conversion if the stock trades at $1.00 or above for ten consecutive days. The investor receives the right to nominate one board member and can participate in future financings to maintain its pro‑rata stake. Proceeds are earmarked for working capital, ISO 13485/QMS audit completion, and a Health Canada registration submission. Closing is expected on or around June 19, 2026.
The financing is material because it directly addresses Light AI’s immediate liquidity crisis while imposing highly unfavorable terms. As of March 31, 2026, the company had only C$4.6 million in cash and burned C$1.9 million in operating cash during Q1 2026. Without fresh capital, the runway extended to roughly three quarters, leaving no margin for unexpected delays. The C$5 million infusion effectively doubles the company’s cash position and buys time to complete its ISO audit and Health Canada filing.
However, the terms reveal a deeply stressed bargaining position. The conversion price of $0.125 is a fraction of the $0.55 per unit pricing of the January 2025 equity raise, indicating a dramatic deterioration in the company’s valuation. If fully converted, the principal alone would add roughly 40 million shares, while the warrants introduce another 40 million shares of potential dilution—a major overhang for existing shareholders. The 12% interest rate and the secured nature of the debt underscore the risk the lender perceives. The board nomination right hands MV Capital significant influence, and the forced‑conversion trigger at $1.00 appears highly aspirational relative to the current implied share price. All these elements point to a rescue financing that is both dilutive and expensive, reflecting the market’s lack of confidence in Light AI’s near‑term prospects.
Previous management guidance had targeted commercialization in mid‑2026 and suggested sufficient capital beyond Q3 2026. This financing, though extending the runway, comes at the cost of severely discounted equity and potential loss of board control. The net effect is negative for existing shareholders.
Light AI Inc. is a medical‑diagnostics technology company that has developed a smartphone‑based artificial intelligence platform capable of detecting Group A Streptococcus (Strep A) from camera images. Its flagship product, QuickScan™ Strep A, achieved Version 1.0 completion in November 2025, claiming 96.57% overall accuracy and 100% negative predictive value in pre‑FDA validation studies. The company is now in the transition from research and development to commercialization, planning a pilot study in urgent‑care settings with a major healthcare provider. Future indications include eye and skin conditions. Light AI’s strategy hinges on a “Digital Clinical Lab” model that reduces reliance on conventional diagnostic infrastructure.